Merck KGaA (FRA:MRK) received a €103.00 ($114.44) target price from equities research analysts at Morgan Stanley in a research note issued to investors on Monday. The firm presently has a a “neutral” rating on the stock.
A number of other equities research analysts have also commented on the stock. Commerzbank AG set a €101.00 ($112.22) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Friday, July 22nd. Citigroup Inc. set a €115.00 ($127.78) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Tuesday, July 26th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Merck KGaA in a report on Thursday, July 21st. Bank of America Corp. set a €98.00 ($108.89) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Friday, April 22nd. Finally, DZ Bank AG restated a “buy” rating on shares of Merck KGaA in a report on Thursday, July 14th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of €100.55 ($111.72).
Merck KGaA (FRA:MRK) opened at 95.258 on Monday. The firm has a market cap of €41.42 billion and a price-to-earnings ratio of 29.805. Merck KGaA has a 12 month low of €70.87 and a 12 month high of €100.00. The stock’s 50 day moving average is €96.69 and its 200-day moving average is €87.29.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/18/merck-kgaa-mrk-pt-set-at-103-00-by-morgan-stanley.html
Merck KGaA Company Profile
Receive News & Ratings for Merck KGaA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck KGaA and related companies with MarketBeat.com’s FREE daily email newsletter.